NCT00558428
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
See it on ClinicalTrials.gov ↗1,097 people
37.8%
62.2%
415 womenmiddle line = equal numbers682 men
- Phase
- PHASE3
- Paid for by
- Boehringer Ingelheim
- Finished
- —
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 54.2 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“…table means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable methods of birth control include the transdermal patch, oral, implantable or injectable contrace…”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable metho…”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“any clinically significant hepatic impairment (e.g. clinically significant cholestasis, biliary obstructive disorder or hepatic insufficiency)”
Study titles and rules are shown in their original English.